Enrique Grande, MD, on Adrenocortical Carcinoma: Phase II Results on Cabozantinib Plus Atezolizumab

February 05, 2024 By The ASCO Post Staff

Enrique Grande, MD, of MD Anderson Cancer Center Madrid, discusses findings from the CABATEN/GETNE-T1914 study, in which cabozantinib plus atezolizumab showed modest activity in patients with locally advanced or metastatic adrenocortical carcinoma, a rare malignancy with a poor prognosis and limited therapeutic options. According to Dr. Grande, the existence of long-lasting responders makes it worthwhile to continue investigating predictive factors that may help to select patients for this combination therapy (Abstract 1).

Related Content